
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, allowing for the upcoming commencement of U.S. manufacturing of its proprietary Alpha DaRT technology, anticipated to start in 2026. The company has maintained a strong cash position which is critical for its continued development and commercialization efforts in the oncology sector. Despite a net loss of $11.7 million for the period, slightly exceeding prior estimates, the potential of Alpha DaRT to address unmet needs in cancer treatment and its solidifying infrastructure point to a positive long-term outlook for the company's stock.
Bears say
Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting ongoing financial challenges as the company navigates critical stages of development for its Alpha DaRT technology. The company faces significant risks, including the potential failure of clinical trials, obstacles in securing regulatory approval in the U.S., and challenges related to achieving commercial success in a competitive market. Additionally, the threat of potential dilution further complicates the investment outlook, raising concerns over the company's ability to stabilize and grow its financial position in the near term.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares